Mike van Dulken, Head of Research at Accendo Markets, commented: AstraZeneca (AZN) shares are today registering their first bounce in 7 days as investors react to the positive news that the pharmaceutical giant has increased FY 2012 earnings guidance from $6.00 to $6.30 per share. This comes on the back of the group announcing a…
Bullbearings – 8 Aug 2012
Mike van Dulken, Head of Research at Accendo Markets, commented: Aviva’s interim results tomorrow are likely to show operating profits down 10% to £1bn, dented by weather-related claims. However, focus may be on updates regarding the restructuring process launched last month by interim executive John McFarlane. Income investors will be hoping the 10p interim dividend…
Morningstar – 8 Aug 2012 http://www.morningstar.co.uk/uk/news/articles/107665/UK Index -Steady%3B-BoE-Cuts-Economic-Growth-Forecast.aspx
Mike van Dulken, Head of Research at Accendo Markets, commented: Rio Tinto’s H1 2012 results are slightly better than consensus was looking for with underlying profits of $5.2bn beating market expectations of $5.04bn (EPS $2.78 beat market’s $2.73). In terms of outlook, the company has echoed the message from most of its sector peers, highlighting…
Rio Tinto’s H1 results tomorrow are likely to highlight similar trends to those already reported by sector peers. Slowing economic growth (most notably from China, but also US and Europe) and weaker commodity prices will probably hit top-line growth, while rising costs dent margins. Given the importance of iron ore (just announced big CAPEX boost…